STAT+: In China, a flood of controversial clinical trials slows to a trickle
Following patient deaths, China restricts investigator-initiated biotech trials, leaving rare disease families and US investors facing an uncertain future.
Reported by STAT. We will add other newspapers as they cover it.
How the newspaper covers this story
STAT+: In China, a flood of controversial clinical trials slows to a trickle
Following patient deaths, China restricts investigator-initiated biotech trials, leaving rare disease families and US investors facing an uncertain future.
